Questions About ADHD Medication

**MEDICATION & SUBSTANCE USE RISK**

Is risk for substance use reduced in adolescents with ADHD who are treated with stimulant medications?

Many parents of youth with ADHD are concerned about whether treating their child’s ADHD with stimulant medications may increase the risk for illicit substance use. This study compared data collected from two samples: teens with ADHD who took part in an ADHD medication study, and teens with and without ADHD who were involved in a naturalistic, non-medication study. The researchers compared the youth who were in the medication study to those who were not on self-reported drug and alcohol use, and found that rates of substance use were actually lower in the teens enrolled in the medication trial. This suggests that, among teens and under conditions of close monitoring of stimulant medication treatment, there is not increased risk for alcohol and substance use.


**POLYPHARMACY & ADHD**

What is the prevalence of multi-medication treatment in newly diagnosed children with ADHD, and how does this change over time?

Although medication is a common and evidence-based treatment for ADHD, little research has focused on the questions of prevalence, efficacy, and safety of polypharmacy—or the combined use of multiple medications—in ADHD. This study focused on describing the types of medications newly diagnosed children with ADHD receive, and how their medication profiles changed over a five-year period. Using data from Medicaid billing records of 16,626 children who were first diagnosed with ADHD between three and fourteen years of age (with no prior psychotropic medication use), the researchers examined the medications prescribed over a period of five years. A large proportion of the children received stimulants (79%) as well as non-ADHD medications such as antidepressants (33%) and alpha-agonists such as clonidine or guanfacine (23%).

In terms of polypharmacy, 25% of the children received multiple medications at least once. Increases in the use of non-ADHD medications and polypharmacy were seen over time but only among children who were diagnosed with ADHD at earlier ages, between three and nine years. This may be because children who are diagnosed younger have more severe symptoms or co-occurring challenges, although the increase in polypharmacy was only partially explained by increases in additional diagnoses. Ultimately, this study suggests that further research is needed in order to understand the effects of polypharmacy and to refine and improve quality of care, especially among younger children with ADHD.


Meghan Miller, PhD, is an assistant professor in the department of psychiatry and behavioral sciences and the MIND Institute at the University of California, Davis, where her research focuses on identifying the earliest behavioral manifestations of ADHD and autism spectrum disorder. Dr. Miller received the CHADD Young Scientist Research Award in 2015 and her current work is funded by the National Institute of Mental Health.